Ahmedabad: The infrastructure work at the ambitious bulk drug park at Jambusar is expected to be completed by the end of this year. The bulk drug park is being developed to decrease import dependence for active pharmaceutical ingredients (API), especially from China. Gujarat Industrial Development Corporation (GIDC) is working as the state implementation agency (SIA), and it is likely that applications for proposed investments will be invited after June.
A senior GIDC official said, “The infrastructure development work will be completed by the end of this year. The park will have common infrastructure like effluent treatment, sewage treatment, integrated treatment, storage and disposal facility (TSDF), research and development facility, common facility centre, marine discharge, common steam supply, common solvent recovery system, lab testing facility, etc. We will start the allotment process after June.”
The pharma bulk drug park is a strategic initiative aligning with the govt’s Aatmanirbhar Bharat vision. It will facilitate the local production of critical API, reducing dependency on imports and potentially lowering costs. This development is expected to attract investments and create job opportunities, contributing to the economy’s growth.
IDMA president Viranchi Shah said, “Gujarat is the pharma hub of Gujarat with around 28% share in exports and 32% share in total production. The industry is awaiting land allocation at the bulk drug park, which will be the first in the country to have all the common facilities that will help the industry to produce APIs at competitive rates. India is a global medicine supplier, so we have a strong formulation ecosystem, and this park will help us to get raw materials locally. Also, a number of countries will prefer buying Indian APIs, and therefore, there will be good export opportunities as well for our industry.”
According to sources, the manufacturing of around 51 products, including amoxicillin, azithromycin, cephalexin, vitamin B1 and B6, and acyclovir, will be encouraged at this park to reduce import dependence.
The central govt will provide assistance of around Rs 1,000 crore for the development of this park.
Ahmedabad: The infrastructure work at the ambitious bulk drug park at Jambusar is expected to be completed by the end of this year. The bulk drug park is being developed to decrease import dependence for active pharmaceutical ingredients (API), especially from China. Gujarat Industrial Development Corporation (GIDC) is working as the state implementation agency (SIA), and it is likely that applications for proposed investments will be invited after June.
A senior GIDC official said, “The infrastructure development work will be completed by the end of this year. The park will have common infrastructure like effluent treatment, sewage treatment, integrated treatment, storage and disposal facility (TSDF), research and development facility, common facility centre, marine discharge, common steam supply, common solvent recovery system, lab testing facility, etc. We will start the allotment process after June.”
The pharma bulk drug park is a strategic initiative aligning with the govt’s Aatmanirbhar Bharat vision. It will facilitate the local production of critical API, reducing dependency on imports and potentially lowering costs. This development is expected to attract investments and create job opportunities, contributing to the economy’s growth.
IDMA president Viranchi Shah said, “Gujarat is the pharma hub of Gujarat with around 28% share in exports and 32% share in total production. The industry is awaiting land allocation at the bulk drug park, which will be the first in the country to have all the common facilities that will help the industry to produce APIs at competitive rates. India is a global medicine supplier, so we have a strong formulation ecosystem, and this park will help us to get raw materials locally. Also, a number of countries will prefer buying Indian APIs, and therefore, there will be good export opportunities as well for our industry.”
According to sources, the manufacturing of around 51 products, including amoxicillin, azithromycin, cephalexin, vitamin B1 and B6, and acyclovir, will be encouraged at this park to reduce import dependence.
The central govt will provide assistance of around Rs 1,000 crore for the development of this park.